Real-world activity of sacituzumab govitecan for metastatic breast cancer

被引：0
|
作者：
Morganti, S. [1 ]
Kusmick, R. [1 ]
Hughes, M. E. [1 ]
Braso-Maristany, F. [2 ]
Smith, K. [1 ]
Tarantino, P. [1 ]
Vega Leon, M. D. R. [3 ]
Grinda, T. [1 ]
Pardo, F. [4 ]
Dvir, K. [1 ]
Suggs, G. [1 ]
Buck, S. [1 ]
Skeffington, M. [1 ]
Garrido-Castro, A. C. [1 ]
Parsons, H. [1 ]
Sammons, S. [1 ]
Prat, A. [5 ]
Lin, N. [1 ]
Tolaney, S. M. [1 ]
Giordano, A. [1 ]
机构：
[1] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA USA
[2] Inst Invest Biomed August Pi & Sunyer, Dept Oncol, IDIBAPS Fundacio Recerca Clin Barcelona, Barcelona, Spain
[3] VHIO Vall dHebron Inst Oncol, Genom Dept, Barcelona, Spain
[4] Reveal Genom SL, Barcelona, Spain
[5] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.339
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
391P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [31] Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan
    Mamtani, R.
    Katz, J.
    An, R.
    Boateng, F.
    Ghazi, Y.
    Brockman, M.
    Sierecki, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1148 - S1149
  • [32] Sacituzumab govitecan in triple-negative breast cancer
    de Nonneville, Alexandre
    Goncalves, Anthony
    Mamessier, Emilie
    Bertucci, Francois
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [33] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [34] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [35] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
    Puskulluoglu, Miroslawa
    Pieniazek, Malgorzata
    Las-Jankowska, Manuela
    Streb, Joanna
    Ziobro, Marek
    Pacholczak-Madej, Renata
    Kilian-Van Miegem, Paulina
    Rudzinska, Agnieszka
    Grela-Wojewoda, Aleksandra
    Lacko, Aleksandra
    Jarzab, Michal
    Polakiewicz-Gilowska, Anna
    ONCOLOGY AND THERAPY, 2024, 12 (04) : 787 - 801
  • [37] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
    Connie Kang
    Targeted Oncology, 2024, 19 : 289 - 296
  • [38] Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
    Rizzo, A.
    Rinaldi, L.
    Massafra, R.
    Cusmai, A.
    Guven, D. C.
    La Forgia, D.
    Latorre, A.
    Giotta, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S356 - S356
  • [39] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [40] Real world study of racial disparities associated with toxicities of sacituzumab govitecan
    Priyadarshini, Shista
    Petucci, Justin
    Katoch, Avnish
    Honavar, Vasant
    Vasekar, Monali K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345